![](/fileadmin/_processed_/csm_NALFD_model_7770420204.png)
DefiniGEN and Atelerix prevent freezing damage in cell models
The agreement between the British companies combines DefiniGEN’s iPSC hepatocytes (Opti-Heps) with Atelerix's hydrogel preservation technology, which...
![](/fileadmin/_processed_/csm_china_vs_usa_boxing-web_647d130897.jpg)
BIOSECURE Act could affect half of US biopharmaceutical development
In January 2024, the US Senate and House of Representatives introduced the BIOSECURE Act to prevent US companies that collaborate with "foreign...
![](/fileadmin/_processed_/csm_puppy-1207816_1280_b8d31894a0.jpg)
First dog snack from microbial protein
Single cell protein specialist MicroHarvest GmbH is set to co-develop the very first pet feed reducing the carbon dioxide pawprint of dogs in...
![](/fileadmin/_processed_/csm_dollars-499481_1280-_Gerd_Altmann_pixabay_55a91b9ae7.jpg)
Forbion closes first Bioeconomy Fund with US$75m
Life Science investor Forbion opens a new sector for its lead partners who were eager to put money into industries within the ESG standards. At...
![](/fileadmin/_processed_/csm_Peter_Sondermann__c__Tacalyx_d5b3b6d2e0.jpg)
Tacalyx' extends seed capital financing
Tacalyx GmbH, the 2019 spin-out from Peter Seeberger's glycan research group, has doubled its seed funding from €7m to to a bit over €14m to advance...
![](/fileadmin/_processed_/csm_drugs_pills_-web_4e35a70ff4.jpg)
Ten drug recommendations by EMA
The committee recommended end of June granting a marketing authorisation for Balversa (erdafitinib), for the treatment of adult...
![](/fileadmin/_processed_/csm_Neurosense-pipeline_38841e73e1.png)
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Under the agreement with Lonza AG, NeuroSense Therapeutics Ltd will advance early diagnosis and treatment in the neurodegeneration field. Last...